 |
|
Inducing Melanoma for Cancer Vaccine Development
March 28, 2006Cancer vaccines are being investigated in early-phase clinical trials around the world, with many of those trials recruiting patients with melanoma. Although tumor regressions have been seen in 10% to 20% of patients with metastatic melanoma, the great promise of cancer vaccines-controlling tumor growth and cancer spread without serious side-effects-remains as yet unrealized. This could be set to change with the publication of a new mouse model technology in Cancer Research, the journal of the American Association of Cancer Research, from a multi-national team led by investigators at the Brussels Branch of the international Ludwig Institute for Cancer Research (LICR).
"Melanoma has been a focus of cancer vaccine development because many melanoma-specific vaccine targets, so-called 'cancer antigens', have been defined," says the study's senior author, LICR's Dr. Benoit Van den Eynde. "However, we have a limited understanding of how most, but not all, melanomas evade an immune system that has been primed to detect and destroy cancer cells carrying one of these defined cancer antigens."
According to Dr. Van den Eynde, this is due in part to the lack of appropriate animal models in which detailed immunological analyses can be performed before and after vaccination. "The models we use to investigate cancer vaccines at the preclinical level either have a defined cancer antigen in a transplanted tumor, or they have an 'original' tumor that doesn't have a defined antigen. However, in human clinical studies, we have original tumors with defined antigens. So there has been a need for a mouse model that more closely follows the human model."
Thus the Institute that first cloned mouse and human cancer antigens, allowing the rational design of cancer vaccines, has developed a model in which melanoma with a defined cancer antigen can be induced. The model has been engineered to have several mutations found to occur together in human melanoma, and so closely mimics the genetic profile of cancers treated in the clinic. The team, which is comprised of investigators from Belgium, France and The Netherlands, has already begun characterizing a cancer antigen-specific immune reaction observed before the mice were even vaccinated, which they hope will lead to a further understanding of spontaneous melanoma regressions.
Dr. Jill O'Donnell-Tormey, Executive-Director of New York's Cancer Research Institute, which was founded in 1953 specifically to foster cancer immunology research, believes that this model may yield information crucial for cancer vaccines for other tumor types and not just melanoma. "We have clinical trials for cancer antigens for sarcoma, for melanoma, and for breast, prostate, lung and ovarian cancers. We're learning a lot from these trials, but we could learn a lot more if we have a model like this, which selectively expresses each of our target antigens. Just one example might be the analysis of the immune response to cancer antigens during the early stages of cancer onset and progression, which might indicate if there is an optimum time for vaccination."
Ludwig Institute for Cancer Research
Thus the Institute that first cloned mouse and human cancer antigens, allowing the rational design of cancer vaccines, has developed a model in which melanoma with a defined cancer antigen can be induced. The model has been engineered to have several mutations found to occur together in human melanoma, and so closely mimics the genetic profile of cancers treated in the clinic. The team, which is comprised of investigators from Belgium, France and The Netherlands, has already begun characterizing a cancer antigen-specific immune reaction observed before the mice were even vaccinated, which they hope will lead to a further understanding of spontaneous melanoma regressions.
Dr. Jill O'Donnell-Tormey, Executive-Director of New York's Cancer Research Institute, which was founded in 1953 specifically to foster cancer immunology research, believes that this model may yield information crucial for cancer vaccines for other tumor types and not just melanoma. "We have clinical trials for cancer antigens for sarcoma, for melanoma, and for breast, prostate, lung and ovarian cancers. We're learning a lot from these trials, but we could learn a lot more if we have a model like this, which selectively expresses each of our target antigens. Just one example might be the analysis of the immune response to cancer antigens during the early stages of cancer onset and progression, which might indicate if there is an optimum time for vaccination."
Ludwig Institute for Cancer Research
Cancer Vaccine Current Events and Cancer Vaccine News RSSCommon diabetes drug may 'revolutionize' cancer therapies
Researchers at McGill University and the University of Pennsylvania have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency of vaccines and cancer treatments.
Microparticle immune response modifier shows broad effects against recurrent or metastatic cancer
MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced.
Goodbye needle, hello smoothie
Instead of a dreaded injection with a needle, someday getting vaccinated against disease may be as pleasant as drinking a yogurt smoothie.
Implants mimic infection to rally immune system against tumors
Bioengineers at Harvard University have shown that small plastic disks impregnated with tumor-specific antigens and implanted under the skin can reprogram the mammalian immune system to attack tumors.
Chronic inflammation can help nurture skin cancer, study shows
Inflammation, a frontline defense against infection or disease, can help nurture skin cancer, researchers have found.
Vaccine against HER2-positive breast cancer offers complete protection in lab
Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity.
Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show
Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease.
Math could help cure leukemia
When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.
Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
One of the shortcomings of a therapy that uses millions of identical antibodies to boost the immune system's attack on cancer cells is that many patients whose tumors recede in response to the treatment also experience serious inflammatory problems, such as severe diarrhea and rashes.
Resisting lung cancer recurrence
What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years" This concept may no longer be a fantasy.
More Cancer Vaccine Current Events and Cancer Vaccine News Articles
 |
Cancer Vaccines and Tumor Immunity by Rimas Orentas (Author), James W. Hodge (Author), Bryon D. Johnson PhD (Author) Cancer Vaccines and Tumor Immunity offers a review of the basic scientific discoveries that have moved forward into clinical trials. Presented in the context of real-world human research and experimentation, these major scientific advances demonstrate how our understanding of immune activation, T-regulatory cells, and autoimmunity will impact cancer vaccine design. The authors also explain how vaccination in the context of bone marrow transplantation will open new avenues for clinical study in the future. |
 |
Using the Immune System to Treat Cancer |
 |
The HPV Vaccine Controversy: Sex, Cancer, God, and Politics: A Guide for Parents, Women, Men, and Teenagers by Shobha S Krishnan (Author) The Human Papilloma Virus, so-called HPV, is one of the most widespread sexually transmitted diseases in America, with more than 20 million infected now and more than 6 million new cases detected each year. It is estimated that at least 50 percent of all sexually active people will be infected during their lifetimes. And while the silent disease may cause no symptoms in most cases, two strains of HPV cause some 70 percent of all cervical cancer, which strikes more than 10,000 women in the United States alone each year. So it is with great fanfare than an HPV vaccine, tested around the world and approved by the US government in 2006, is being marketed. But controversy surrounds the vaccine, which is being recommended for girls as young as 9 and may be mandated by state governments. In... |
 |
Teaching About Immunity Kit by American Educational Products This kit clearly displays the interrelated workings of the Immunity System. Attack an invading anigen with a phagocyte or monbyte. Produce macrophages. T-Cells, B-Cells, Plasma Cells, and antibodies. Clone T and B cells to produce Helper, Killer, Memory and Suppression cells. Demonstrate the operation of AIDS, Cancer, Vaccines, Allergies, Autoimmune reactions and more right on the board. Students can readily participate in the "hands on" activities. The Plastick pieces will not break, chip, tear, peel or wear out! Comes complete with a 30" X 40" Demonstration Board, mounting legs, and Teacher's Guide with detailed lesson plans plus reproducible student worksheets. |
 |
The Virus and the Vaccine: Contaminated Vaccine, Deadly Cancers, and Government Neglect by Debbie Bookchin (Author), Jim Schumacher (Author) 'This well-researched, well-documented book unfurls a compelling scientific saga...written with the zing of a medical thriller.'-The atlanta Journal-Constitution A gripping medical detective story, this book raises major ques-tions about vaccine safety and regulation and shows how power, politics, and prejudice influence the health policy decisions that affect our lives. Jonas Salk's polio vaccine is regarded as a verit-able medical miracle, for it largely eradicated one of the most feared diseases of the twentieth century. But the story of the vaccine has a dark side that has never been fully told before. Between 1954 and 1963, some 98 million Americans received polio vaccinations contaminated with a carcinogenic monkey virus, known as SV40. The government downplayed the incident, and it... |
 |
Charlie Rose - The Charlie Rose Science Series, Episode 4 (April 18, 2007) The Fourth Episode in The Charlie Rose Science Series, an hour on the latest in the rapidly evolving field of cancer research. Charlie is joined by, Sir Paul Nurse (President of The Rockefeller University), Harold Varmus (President, Memorial Sloan-Kettering Cancer Center), David Nathan (President Emeritus, Dana-Farber Cancer Institute), Deb Schrag (Memorial Sloan-Kettering Cancer Center) and Martin Abeloff (Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins). The panel discusses advances in screenings and early detection and other methods of prevention like the HPV vaccine, the changes in accuracy of diagnoses, and cancer treatments such as targeted therapies. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy... |
 |
Handbook of Cancer Vaccines (Cancer Drug Discovery and Development) by Michael A. Morse (Editor), Timothy M. Clay (Editor), H. Kim Lyerly (Editor) An authoritative survey of the scientific background for therapeutic cancer vaccines, the challenges to their development, and their current uses in treating cancer. The authors examine the basic issues that effect all vaccines (such as immune adjuvants and prime-boost strategies), describe the methods for antigen discovery, and review the preclinical development phases for each major vaccine strategy. They also spell out the clinical results for cancer vaccines now beginning to be used in the treatment of many common cancers. |
|
The Conquest of Cancer: Vaccines and Diet by Virginia Livingston-Wheeler (Author) | |
 |
History of Disease & Sickness 5 DVD Collection: Polio, Cancer, Tuberculosis, TB, Infectious Diseases, & Human Health Films 5 DVD Collection Disc 1 Polio Disease & Poliomyelitis Virus Vaccine & Treatment Films (1950s - 1960s) Disc 2 Disease & Infections Films (1940s) Disc 3 Cancer Films (1940s - 1960s) Disc 4 Tuberculosis TB Films (1930-1955) Disc 5 US Disease Quarantine Film (1950s) |
 |
Vaccines for the Prevention of Cervical Cancer (Oxford Oncology Library) by Peter L. Stern (Editor), Henry C. Kitchener (Editor) Cervical cancer is the second most common form of cancer found in women, and it is responsible for more than a quarter of a million deaths worldwide each year. With approximately 70% of cervical cancers now known to be caused by two types of the human pailloma virus (HPV), there is great interest surrounding the approval of the first preventative vaccines for clinical use. Despite this excitement, many questions remain about how the new vaccines should best be implemented and how cervical cnancer screening will change following vaccination. Part of the Oxford Oncology Library series, this practical handbook provides an overview of the role of HPV in the pathology of cervical cancer and its current screening and management, the principles of immune control of HPV infection in cervical... |
| © 2009 BrightSurf.com |